Xofigo

DRUG3 trials

Sponsors

Angela Taber MD, Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie, Bayer

Conditions

Bone MetastasesClear-cell Metastatic Renal Cell CarcinomaNon Small Cell Lung Cancer With Bone MetastatsesProstate Cancer, Castration Resistant

Phase 1

Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)

Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieBone Metastases, Clear-cell Metastatic Renal Cell Carcinoma

Start: 2016-10-31End: 2021-02-28Target: 42Updated: 2016-11-08

Phase 2

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

CompletedNCT02283749

Angela Taber MDNon Small Cell Lung Cancer With Bone Metastatses

Start: 2015-09-30End: 2018-11-13Updated: 2021-02-02

Unknown Phase

Multi-academic Center Study of Xofigo Patients

CompletedNCT03419442

BayerProstate Cancer, Castration Resistant

Start: 2018-12-03End: 2019-10-22Updated: 2020-10-22

Related Papers

Radium-223 following front-line chemotherapy for patients with non-small cell lung cancer and bone metastases.

Journal of Clinical Oncology2018-05-204 citations